METROPOLIS2023-10-012023-12-31 METROPOLIS2023-10-012023-12-31 METROPOLIS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member METROPOLIS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member METROPOLIS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member METROPOLIS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member METROPOLIS2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 542650 METROPOLIS NOTLISTED Metropolis Healthcare Limited Equity 2023-04-01 2024-03-31 2024-02-02 2024-01-26 INR Lakhs Third quarter 14:55:00 18:20:00 2024-02-02 2024-02-02 Not applicable Single segment Pathology Services 2023-10-01 2023-12-31 Unaudited Standalone 2694087000.00 51885000.00 2745972000.00 521261000.00 0.00 0.00 629645000.00 52437000.00 241389000.00 954927000.00 2399659000.00 346313000.00 0.00 346313000.00 86020000.00 -6680000.00 79340000.00 0.00 266973000.00 0.00 0.00 0.00 0.00 266973000.00 -7220000.00 259753000.00 0.00 0.00 102445000.00 2 5.21 5.19 0.00 0.00 5.21 5.19 1. The standalone financial results ( FR ) have been prepared in accordance with the recognition and measurement principles of Ind AS prescribed under Section 133 of the Companies Act read with the relevant rules issued thereunder and other accounting principles generally accepted in India. 2. The standalone FR of the Company have been reviewed by the Audit Committee at their meeting held on 02 Feb 24 and thereafter approved by the Board at their meeting held on 02 Feb 24. The statutory auditors have issued an unmodified review report on the above standalone FR. 3. Disclosure of segment-wise information is not applicable, as pathology services is the Company's only business segment. 4. The Board of the Company, at their meeting held on 11 Feb 22, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan’s Hitech Diagnostic Centre Private Limited (‘Hitech’), a WOS of the Company, to be carried out under the provisions of IBC, 2016. The Board of Hitech in their meeting dated 01 Apr 22 and the members of Hitech in their EOGM held on 01 Apr 22 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process. Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and w.e.f 04 Jun 22. 5. On Nov 04, 23, the Board approved grant of 2000 Restricted Stock Units on the recommendation of the NRC, pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company. This is in addition to the RSU's approved in the previous quarters. 6. Other expenses for the quarter and nine months period ended 31 Dec 23 includes Rs 418.85 lakhs on account of provision for doubtful debtors as an outcome of investigation relating to a whistle blower complaint. 7. The Board has accorded their approval for entering into a Settlement agreement with the equity shareholder(s) of Star Metropolis Health Services Middle East LLC-Dubai, associate of the Company inter-alia to enable liquidation of the Associate as per the applicable laws. For detailed Note, kindly refer the standalone FR of the Company which are made available at www.metropolisindia.com, www.nseindia.com and www.bseindia.com. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 8111586000.00 99778000.00 8211364000.00 1612122000.00 0.00 0.00 1854675000.00 166885000.00 654953000.00 2799183000.00 7087818000.00 1123546000.00 0.00 1123546000.00 311059000.00 -28608000.00 282451000.00 0.00 841095000.00 0.00 0.00 0.00 0.00 841095000.00 -21662000.00 819433000.00 0.00 0.00 102445000.00 2 16.42 16.36 0.00 0.00 16.42 16.36 Laboratory testing charges 20240000.00 Other expenses 934687000.00 Laboratory testing charges 70135000.00 Other expenses 2729048000.00 7220000.00 21662000.00 0.00 0.00